GlassScriptPhysician profile
Aurora Madanguit
NPI 1619902855
$6,934.66
in general payments reported to CMS, 2019-2025
32 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $743 · 2021: $1,794 · 2022: $873 · 2023: $1,021 · 2024: $668 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $938.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $658.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.31 | 2020-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $561.98 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.47 | 2022-2025 | Caplyta |
| Pfizer INC. | $388.84 | 2019-2025 | |
| Abbvie INC. | $357.56 | 2021-2025 | |
| Novo Nordisk INC | $353.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $274.57 | 2019-2025 | |
| Lilly USA, LLC | $261.52 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Vanda Pharmaceuticals INC. | $202.16 | 2024-2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $191.00 | 2022-2025 | |
| Mylan Specialty L.P. | $172.38 | 2020-2023 | Yupelri |
| Axsome Therapeutics, INC. | $164.48 | 2023-2025 | Auvelity |
| Allergan, INC. | $148.96 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $126.55 | 2021-2022 | |
| Amgen INC. | $119.64 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $119.58 | 2021-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $119.44 | 2019-2022 | |
| Lundbeck LLC | $117.26 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $90.84 | 2019-2021 | |
| Amarin Pharma, INC. | $84.50 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.47 | 2021-2024 | Trintellix |
| Nabriva Therapeutics, Plc | $45.58 | 2021 | |
| Abbott Laboratories | $44.18 | 2024-2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $42.01 | 2025 | Yupelri |
| Dexcom, INC. | $39.46 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $37.64 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $34.37 | 2021-2022 | |
| Corcept Therapeutics | $34.13 | 2023 | Korlym |
| Ibsa Pharma INC. | $15.05 | 2024 | Licart, Tirosint |
| Nestle Healthcare Nutrition INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Madanguit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.